• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Enterovirus Infections - Pipeline Review, H2 2012 Product Image

Enterovirus Infections - Pipeline Review, H2 2012

  • ID: 2335154
  • November 2012
  • 40 pages
  • Global Markets Direct

Enterovirus Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Enterovirus Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Enterovirus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterovirus Infections. Enterovirus Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Enterovirus Infections.
- A review of the Enterovirus Infections products under development by companies READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Enterovirus Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Enterovirus Infections 7
Enterovirus Infections Therapeutics under Development by Companies 9
Enterovirus Infections Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Enterovirus Infections Therapeutics – Products under Development by Companies 15
Enterovirus Infections Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Enterovirus Infections Therapeutics Development 17
Sinovac Biotech Ltd. 17
Inviragen, Inc. 18
Enterovirus Infections – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
EV-71 Vaccine - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
SLP-0904 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
INV-21 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
EV-71 Vaccine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Vero Cell - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Enterovirus Infections Therapeutics – Drug Profile Updates 30
Enterovirus Infections – Product Development Milestones 32
Featured News & Press Releases 32
Jul 27, 2012: Fluoxetine Effective As Anti-Viral, UCLA Researchers Discover 32
Jun 25, 2012: Sinovac Reports Progress In EV71 Vaccine Phase III Clinical Trial And Commercialization Preparation Status 32
Jun 11, 2012: Sinovac Reports Progress In EV71 Vaccine Phase III Clinical Trial 33
Mar 29, 2012: Sinovac Announces Publication Of Phase I Clinical Data Of EV71 Vaccine For Prevention Of Hand, Foot And Mouth Disease In Journal Vaccine 34
Jan 10, 2012: Sinovac Commences Phase III Clinical Trial For EV71 Vaccine Against Hand, Foot And Mouth Disease 35
Nov 09, 2011: Sinovac Reports Positive Preliminary Phase II Clinical Trial Results For EV71 Vaccine Against Hand, Foot And Mouth Disease 35
Jun 28, 2011: Sinovac Commences Phase II Clinical Trial For EV71 Vaccine 36
May 25, 2011: Sinovac Reports Positive Phase I Clinical Trial Results For EV71 Vaccine Against HFMD 37
Mar 10, 2011: Sinovac Reports Positive Preliminary Phase I Clinical Trial Results For EV71 Vaccine In Adult Group 37
Dec 28, 2010: Sinovac Receives SFDA Approval To Commence Clinical Trials For Inactivated Enterovirus Type 71 Vaccine 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables
Number of Products Under Development for Enterovirus Infections, H2 2012 7
Products under Development for Enterovirus Infections – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Sinovac Biotech Ltd., H2 2012 17
Inviragen, Inc., H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Enterovirus Infections Therapeutics – Drug Profile Updates 30

List of Figures
Number of Products under Development for Enterovirus Infections, H2 2012 7
Products under Development for Enterovirus Infections – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos